Skip to main content

Remote Job Finders (RJF)

‘Execution, Execution, Execution’: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of reallocating resources to the company’s “main core” of metabolic disease.

FDA In Flux, Pfizer Talks to Trump on MFN, Merck Cuts 6K Jobs, More

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest rejection reportedly driven by FDA’s top cancer regulator Richard Pazdur; Merck’s $3 billion savings push claims 6,000 jobs; and Pfizer CEO Albert Bourla addresses President Donald Trump’s new threats around Most Favored Nation drug pricing.

Building Pharma’s Farm System: Eli Lilly, Boehringer Ingelheim, More Invest in the Future

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and venture funds to uncover cutting-edge scientific trends, determine their future focus points and even carve out a niche in an emerging geographical hotspot.
Scroll to top